Buccal Delivery of Chemotherapy to treat. read more

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was... read more

PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial... read more

Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate... read more

The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support... read more

​​​​​Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI... read more

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce... read more

Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston... read more

Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more